Ellen Shrader

452 total citations
19 papers, 219 citations indexed

About

Ellen Shrader is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Ellen Shrader has authored 19 papers receiving a total of 219 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 9 papers in Hematology and 6 papers in Genetics. Recurrent topics in Ellen Shrader's work include Histone Deacetylase Inhibitors Research (11 papers), Protein Degradation and Inhibitors (8 papers) and Acute Myeloid Leukemia Research (6 papers). Ellen Shrader is often cited by papers focused on Histone Deacetylase Inhibitors Research (11 papers), Protein Degradation and Inhibitors (8 papers) and Acute Myeloid Leukemia Research (6 papers). Ellen Shrader collaborates with scholars based in United States. Ellen Shrader's co-authors include Nathan S. Schlezinger, Mary Beth Tombes, Maciej Kmieciak, Steven Grant, Beata Holkova, Heidi Sankala, John D. Roberts, Wen Wan, Danielle Shafer and Prithviraj Bose and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Ellen Shrader

19 papers receiving 209 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ellen Shrader United States 9 112 79 42 37 33 19 219
Terukazu Enami Japan 10 76 0.7× 68 0.9× 21 0.5× 53 1.4× 76 2.3× 16 225
Yoshimi Nakamura Japan 10 78 0.7× 36 0.5× 61 1.5× 47 1.3× 15 0.5× 39 364
María José Robles‐Frías Spain 7 126 1.1× 92 1.2× 10 0.2× 118 3.2× 13 0.4× 11 330
H Iwashita Japan 9 76 0.7× 33 0.4× 82 2.0× 20 0.5× 45 1.4× 26 257
Karin Papworth Sweden 9 60 0.5× 54 0.7× 43 1.0× 48 1.3× 14 0.4× 12 187
Lucy T. Xu United States 9 71 0.6× 28 0.4× 26 0.6× 75 2.0× 6 0.2× 20 271
Christopher LaGanke United States 9 44 0.4× 193 2.4× 80 1.9× 72 1.9× 11 0.3× 28 287
John Taper Australia 7 35 0.3× 94 1.2× 53 1.3× 60 1.6× 35 1.1× 11 270
Gabriele Krüger Germany 10 163 1.5× 18 0.2× 32 0.8× 45 1.2× 10 0.3× 19 389
Andrea Alonso United States 5 71 0.6× 56 0.7× 12 0.3× 26 0.7× 33 1.0× 7 250

Countries citing papers authored by Ellen Shrader

Since Specialization
Citations

This map shows the geographic impact of Ellen Shrader's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen Shrader with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen Shrader more than expected).

Fields of papers citing papers by Ellen Shrader

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen Shrader. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen Shrader. The network helps show where Ellen Shrader may publish in the future.

Co-authorship network of co-authors of Ellen Shrader

This figure shows the co-authorship network connecting the top 25 collaborators of Ellen Shrader. A scholar is included among the top collaborators of Ellen Shrader based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen Shrader. Ellen Shrader is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Poklepovic, Andrew, Sarah Gordon, Sejal Kothadia, et al.. (2024). A phase 1 study of regorafenib and sildenafil in adults with advanced solid tumors. Anti-Cancer Drugs. 35(5). 450–458. 2 indexed citations
2.
Shafer, Danielle, Michelle A. Rudek, Maciej Kmieciak, et al.. (2023). Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies. Cancer Chemotherapy and Pharmacology. 91(3). 281–290. 14 indexed citations
3.
Poklepovic, Andrew, Sarah Gordon, William P. McGuire, et al.. (2020). Phase I study of regorafenib and sildenafil in advanced solid tumors.. Journal of Clinical Oncology. 38(15_suppl). 3593–3593. 4 indexed citations
4.
Holkova, Beata, Danielle Shafer, Victor Yazbeck, et al.. (2020). Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome. Leukemia & lymphoma. 62(5). 1187–1194. 9 indexed citations
5.
Shafer, Danielle, Mary Beth Tombes, Ellen Shrader, et al.. (2020). Phase I trial of dimethyl fumarate, temozolomide, and radiation therapy in glioblastoma. Neuro-Oncology Advances. 2(1). vdz052–vdz052. 16 indexed citations
6.
Shafer, Danielle, Zhijian Chen, Timothy Harris, et al.. (2017). Phase I trial of dimethyl fumarate, temozolomide, and radiation therapy in glioblastoma multiforme.. Journal of Clinical Oncology. 35(15_suppl). 2060–2060. 2 indexed citations
7.
8.
Poklepovic, Andrew, Sarah Gordon, Danielle Shafer, et al.. (2016). Phase I study of pemetrexed with sorafenib in advanced solid tumors. Oncotarget. 7(27). 42625–42638. 8 indexed citations
9.
Holkova, Beata, Maciej Kmieciak, Prithviraj Bose, et al.. (2015). Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas. Leukemia & lymphoma. 57(3). 635–643. 17 indexed citations
10.
11.
Holkova, Beata, Jeffrey G. Supko, Matthew M. Ames, et al.. (2013). A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2. Clinical Cancer Research. 19(7). 1873–1883. 26 indexed citations
12.
Holkova, Beata, Maciej Kmieciak, Prithviraj Bose, et al.. (2013). Phase I Trial Of Carfilzomib In Combination With Vorinostat (SAHA) In Patients With Relapsed/Refractory B-Cell Lymphomas. Blood. 122(21). 4375–4375. 4 indexed citations
13.
Holkova, Beata, Thomas C. Shea, Prithviraj Bose, et al.. (2012). Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma. Blood. 120(21). 1794–1794. 4 indexed citations
14.
15.
16.
Holkova, Beata, Lubomir Sokol, Kristy L. Richards, et al.. (2011). A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma. Blood. 118(21). 779–779. 9 indexed citations
17.
Holkova, Beata, Ashraf Badros, Robert B. Geller, et al.. (2011). A Phase II Study of the MEK 1/2 Inhibitor AZD6244 (Selumetinib, ARRY-142866) in Relapsed or Refractory Multiple Myeloma. Blood. 118(21). 2931–2931. 3 indexed citations
18.
Holkova, Beata, Mary Beth Tombes, Ellen Shrader, et al.. (2011). Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis. Blood. 118(21). 2598–2598. 2 indexed citations
19.
Shrader, Ellen & Nathan S. Schlezinger. (1960). Neuro-Ophthalmologic Evaluation of Abducens Nerve Paralysis. Archives of Ophthalmology. 63(1). 84–91. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Terukazu Enami Breakdown of academic impact, for papers by Yoshimi Nakamura Breakdown of academic impact, for papers by María José Robles‐Frías Breakdown of academic impact, for papers by H Iwashita Breakdown of academic impact, for papers by Karin Papworth Breakdown of academic impact, for papers by Lucy T. Xu Breakdown of academic impact, for papers by Christopher LaGanke Breakdown of academic impact, for papers by John Taper Breakdown of academic impact, for papers by Gabriele Krüger Breakdown of academic impact, for papers by Andrea Alonso
Rankless by CCL
2026